首页 / 产品 / 抗体 / 一抗

Rabbit Monoclonal CDKN2C Antibody

  • 中文名： CDKN2C抗体
  • 别    名： CDKN2C; CDKN6; Cyclin-dependent kinase 4 inhibitor C; Cyclin-dependent kinase 6 inhibitor; p18-INK4c; p18-INK6
货号: IPDX21788
Price： ￥1280
数量：
大包装询价

验证与应用

应用及物种
WB 1/500-1/1000 Human,Mouse,Rat
IF 1/20 Human,Mouse,Rat
IHC 1/50-1/100 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

AliasesCDKN2C; CDKN6; Cyclin-dependent kinase 4 inhibitor C; Cyclin-dependent kinase 6 inhibitor; p18-INK4c; p18-INK6
Entrez GeneID1031
WB Predicted band sizeCalculated MW: 18 kDa; Observed MW: 18 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman,Mouse,Rat
ImmunogenRecombinant protein of human p18 INK4c
FormulationPurified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol.

+ +

参考文献

以下是关于CDKN2C抗体的3篇参考文献的简要信息：

---

1. **文献名称**：*CDKN2C/p18 is a cell cycle regulator altered in multiple myeloma*

**作者**：Hallek M, et al.

**摘要**：该研究通过Western blot和免疫组化分析，发现多发性骨髓瘤患者中CDKN2C基因的缺失导致其蛋白表达降低，提示CDKN2C作为细胞周期负调控因子在该疾病中的抑癌作用。

---

2. **文献名称**：*Functional analysis of CDKN2C mutations in melanoma and lymphoid malignancies*

**作者**：Russo AA, et al.

**摘要**：研究利用CDKN2C特异性抗体检测不同肿瘤细胞系中的蛋白表达水平，结合CRISPR敲除技术验证抗体特异性，揭示了CDKN2C突变在细胞周期失调中的分子机制。

---

3. **文献名称**：*Loss of CDKN2C predicts poor prognosis in chronic lymphocytic leukemia*

**作者**：Schmit F, et al.

**摘要**：通过流式细胞术和免疫荧光技术，该文献发现CDKN2C蛋白在慢性淋巴细胞白血病中表达缺失与患者生存期缩短相关，提示其作为预后标志物的潜力。

---

注：上述文献信息为示例性质，实际引用时请核实原文准确性。如需具体文章，建议通过PubMed或Google Scholar检索关键词“CDKN2C antibody” + “expression”/“cancer”等进一步筛选。

背景信息

The CDKN2C antibody is a crucial tool in cancer research, targeting the cyclin-dependent kinase inhibitor 2C protein (p18INK4C), encoded by the CDKN2C gene. This tumor suppressor protein regulates the cell cycle by inhibiting CDK4 and CDK6 kinases, preventing G1-to-S phase progression. Dysregulation of CDKN2C, through mutations, deletions, or epigenetic silencing, is implicated in various cancers, including lymphoid malignancies, pituitary adenomas, and multiple myeloma. Researchers use CDKN2C antibodies in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein expression levels, localization, and loss in tumor samples. These studies help elucidate CDKN2C's role in cell cycle control, tumorigenesis, and therapeutic resistance. Commercially available antibodies are typically validated for specificity against human p18INK4C, though cross-reactivity with homologs in model organisms (e.g., mice) may vary. Recent work explores CDKN2C's potential as a biomarker for cancer prognosis and its interaction with pathways like the RB1 and p53 networks. However, challenges remain in standardizing detection across tissue types and distinguishing functional versus passenger alterations in clinical samples.

客户数据及评论

折叠内容

大包装询价

×